Market News

Stay updated with the latest market trends, earnings, and economic indicators.

Showing news for:HCG
Clear all filters
Infosys Ties Up With IHH Healthcare For AI Led Growth
positive
NDTV Profit 30d ago

Infosys Ties Up With IHH Healthcare For AI Led Growth

Through a partnership with Infosys, IHH seeks to standardise business processes across all its markets starting with Hong Kong, Malaysia, and Singapore.

ALLETECHCGHCG-REHEALTHCAREINFYFinancial ServicesHealthcare
NEWS
neutral
Business Standard - Markets 30d ago

Aegis Logistics Ltd leads gainers in 'A' group

Blue Jet Healthcare Ltd, Wockhardt Ltd, DOMS Industries Ltd and Apar Industries Ltd are among the other gainers in the BSE's 'A' group today, 11 June 2026.

AEGISLOGAPARINDSBLUEJETBLUEWATERBSEDOMSHCGHCG-REHEALTHCAREJETFREIGHTMOHEALTHSJLOGISTICWOCKPHARMACapital GoodsFast Moving Consumer Goods
Analysts project up to 17% upside in healthcare stocks trading at new highs
positive
Business Standard - Markets 30d ago

Analysts project up to 17% upside in healthcare stocks trading at new highs

Apollo Hospitals, Aster DM Healthcare, Sai Life Sciences have rallied up to 27% thus far in FY27; technical analysts remain bullish on these stocks given the favourable chart set-up.

ALIVUSAPOLLOAPOLLOHOSPASTERDMHCGHCG-REHEALTHCAREHEALTHYJFLLIFEJFL-REJLHLRPGLIFESAILIFESUVENCapital GoodsFinancial Services
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplash
positive
ET Markets - Stocks 30d ago

Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplash

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic demand and positive global healthcare trends. Analysts see long-term growth potential from aging populations and innovation. Emerging opportunities from supply chain diversification away from China also present a positive outlook for Indian pharmaceutical companies.

BMETRICSGLOBALHCGHCG-REHEALTHCARELTGILTBEESTVSSCSConsumer ServicesFinancial Services
Nifty 50 target cut by Citi to 26,000 - Key risk factors, top picks explained
positive
CNBC TV18 - Markets 30d ago

Nifty 50 target cut by Citi to 26,000 - Key risk factors, top picks explained

Citi has highlighted Financials, Telecom, Healthcare, Defence and Utilities as their key "overweights", while IT Services, Staples, Metals are their top "underweights." It has also added Hitachi Energy into its list of top picks having initiated coverage on the stock recently.

BFUTILITIEDEFENCEENERGYGKENERGYGROWWDEFNCHCGHCG-REHEALTHADDHEALTHAXISHEALTHCAREHEALTHIETFHEALTHYHPTLKPELLLOYDSMEMODEFENCEMOENERGYPOWERINDIASDL26BEESTOP10ADDTOP15IETFTOP20Capital GoodsConstruction
Further consolidation ahead for Nifty? Here's today's outlook and top picks
positive
Business Standard - Markets 30d ago

Further consolidation ahead for Nifty? Here's today's outlook and top picks

Ajit Mishra of Religare Broking has recommended buying the shares of Fortis Healthcare, RBL Bank, and Eternal today

ABSLBANETFBANKADDBANKBEESBANKBETABANKBETFBANKETFBANKIETFBANKINDIABANKNIFTY1BANKPSUBBNPNBETFBNKETFAXISEBANKNIFTYETERNALFINIETFFORTISGROWWPSUBKHCGHCG-REHDFCNIFBANHDFCPSUBKHDFCPVTBANHEALTHADDHEALTHAXISHEALTHCAREHEALTHIETFHEALTHYNPBETPSUBANKPSUBANKADDPSUBNKBEESPSUBNKIETFPVTBANIETFPVTBANKADDRBLBANKRELIGARESDL26BEESSETFNIFBKTOP10ADDTOP15IETFTOP20Consumer ServicesFinancial Services
India's healthcare transformed in 12 years under PM Modi: Report
positive
ET Markets - Industry 31d ago

India's healthcare transformed in 12 years under PM Modi: Report

India's healthcare sector has seen a major transformation over the last 12 years. Health insurance coverage has expanded significantly. Maternal and child healthcare has improved. Medical infrastructure has seen a substantial increase. The government has focused on making healthcare accessible and affordable for all citizens.

AFFORDABLEALLETECHCGHCG-REHEALTHCAREMEDANTANIVABUPASTARHEALTHCapital GoodsFinancial Services
Carlyle Eyes India IPO For Healthcare RCM Provider After Recent Acquisition
neutral
NDTV Profit 31d ago

Carlyle Eyes India IPO For Healthcare RCM Provider After Recent Acquisition

Carlyle has started discussions with investment banks for a possible India IPO of its healthcare billing venture.

BFINVESTHCGHCG-REHEALTHCAREFinancial ServicesHealthcare
Up 44%+ in June, these healthcare stocks are rallying once again - Investing.com India
neutral
Google News - Investing.com India 31d ago

Up 44%+ in June, these healthcare stocks are rallying once again - Investing.com India

Up 44%+ in June, these healthcare stocks are rallying once againInvesting.com India

HCGHCG-REHEALTHCAREFinancial ServicesHealthcare
Margin play: Why Supertails is doubling down on the lucrative pet healthcare market
positive
LiveMint - Companies 31d ago

Margin play: Why Supertails is doubling down on the lucrative pet healthcare market

With medical services yielding double the margins of retail, the startup is expanding its clinic and pharmacy footprint to anchor itself at the centre of India's formalizing pet economy.

GLOBALPETHCGHCG-REHEALTHCARERETAILSDREAMSV2RETAILCapital GoodsConsumer Services
Pharma in her DNA, Wockhardt scion ready for deep dive in the US
positive
ET Markets - Industry 32d ago

Pharma in her DNA, Wockhardt scion ready for deep dive in the US

Zahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacterial infections and is a significant bet for the company. Zaynich's US approval marks a major breakthrough after decades without new antibiotics. Zahabiya is focused on hospital penetration, physician advocacy, and demonstrating economic value to healthcare systems.

DEEPINDSHCGHCG-REHEALTHCARERSYSTEMSVALUEWOCKPHARMAFinancial ServicesHealthcare
Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift
positive
CNBC TV18 - Markets 32d ago

Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift

Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.

ABSLNN50ETBIOCONBSLGOLDETFHCGHCG-REHEALTHCAREHEALTHYLUPINMANKINDONESOURCESPARCFinancial ServicesHealthcare